Mark Scholz, MD

Curriculum Vitae [ CV ]

A board-certified medical oncologist, Mark C. Scholz, MD, serves as medical director of Prostate Oncology Specialists Inc. in Marina del Rey, CA, a medical practice exclusively focused on prostate cancer. He is also the executive director of the Prostate Cancer Research Institute. He received his medical degree from Creighton University in Omaha, NE. Dr. Scholz completed his Internal Medicine internship and Medical Oncology fellowship at University of Southern California Medical Center.

Dr. Scholz is a strong advocate for patient empowerment. He is the co-author of the book Invasion of the Prostate Snatchers: No More Unnecessary Biopsies, Radical Treatment or Loss of Potency and has written and produced extensive educational material on the subject of prostate cancer in various medias which include DVDs, blogs, newsletters and pamphlets. He is frequently an invited guest speaker in the community at prostate cancer conferences and prostate cancer support groups throughout the world. He is also an educational speaker on behalf of Amgen, Dendreon and Sanofi-Aventis.

Dr. Scholz is also a past president and co-founder of the Prostate Cancer Research Institute (PCRI), a non-profit organization dedicated to patient education and research. PCRI clinical research on the topic of hormone therapy has been published in the Journal of UrologyThe Prostate, and UROLOGY. The PCRI also provides financial support for research endeavors in the area of active surveillance, prostate imaging, and the development of new tumor markers. Future directions for PCRI research are aimed at enhancing the anticancer function of the immune system, developing treatments to prevent bone metastases, and evaluating the impact of nutritional supplements.

Dr. Scholz served as oncology director at the Memorial Campus of the Centinela Freeman Regional Medical Center from 1996-2001. His current hospital affiliations include St. John’s Health Center, Marina del Rey Hospital.  His society memberships include the American Society of Clinical Oncology, American Society of Therapeutic Radiology, American Urologic Associate and European Associate of Urology. He continues as a primary investigator actively supervising a number of ongoing prostate cancer clinical trials and has authored or coauthored over 90 scholarly articles and abstracts in his area of expertise.

LICENSURE

Medical Board of California – Physicians and Surgeons License 1984. G52827
DEA AS2791552
NPI 1588653943

CERTIFICATIONS

American Board of Internal Medicine (Oncology) 1989
American Board of Internal Medicine 1986

Hospital Affiliations

Marina del Rey Hospital, Marina del Rey
Saint John’s Hospital, Santa Monica

EDUCATION

Fellowship  University of Southern California (USC), LAC-USC Medical Center, Los Angeles, Fellowship Medical Oncology, 1986-1988 (Chief Fellow, 1987-1988)
Residency  University of Southern California (USC), LAC-USC Medical Center, Los Angeles, Internal Medicine, 1984-1986
Internship University of Southern California (USC), LAC-USC Medical Center, Los Angeles Internal Medicine, 1983-1984
Medical School  Medical School Creighton University, Omaha, NE – Doctor of Medicine, 1983
Undergraduate  Orange Coast College, Costa Mesa, CA 1973-1974, University of Southern California (USC) Los Angeles, CA 1974-1976, Occidental College, Los Angeles, CA 1976-1978

HONORS AND AWARDS

Nautilus Book Award Gold Winner in Wellness/Prevention/Vitality, 2011. Invasion of the Prostate Snatchers, Ralph H. Blum, Mark Scholz, MD.

Western AUA – Best Poster 2003: PSA Nadir Greater than 0.1 on Combined Hormone Blockade Predicts the Early Development of Androgen Independent Prostate Cancer. Mark C. Scholz, Tom Trilling, Stan A. Brosman, Brad W. Guess, Henry J. Johnson, Richard Y. Lam.

AUA – Best Poster 1997: Anemia Associated with Androgen Deprivation in Prostate Cancer Patients on Combination Hormone Blockade. Stephen B. Strum, John E. McDermed, Mark C. Scholz.

SOCIETY MEMBERSHIPS

American College of Physicians
American Medical Association
American Medical Society
American Society of Clinical Oncology
American Society of Therapeutic Radiology
American Urological Association, Affiliate
California Medical Society
European Association of Urology
Los Angeles County Medical Association

PUBLICATIONS

Crawford, E. David, Mark C. Scholz, Ashok J. Kar, Jeffrey E. Fegan, Abebe Haregewoin, Rajesh R. Kaldate, and Michael K. Brawer. “Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry.” Current Medical Research and Opinion 30, no. 6 (2014): 1025-1031.

Moyad, Mark A., and Mark C. Scholz. “Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial.” Research and Reports in Urology 6 (2014): 71.

Scholz, Mark C., Meg K. Groom, Andrew J. Kaddis, Stephen B. Strum, Robert I. Jennrich, Duke K. Bahn, Patricia J. Chang, Lauren K. Becker, and Richard Y. Lam. “Primary androgen deprivation (AD) followed by active surveillance (AS) for newly diagnosed prostate cancer (PC): a retrospective study.” The Prostate 73, no. 1 (2013): 83-88.

Grimm, Peter, Ignace Billiet, David Bostwick, Adam P. Dicker, Steven Frank, Jos Immerzeel, Mira Keyes et al. “Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.” BJU International 109, no. s1 (2012): 22-29.

Scholz, Mark C., Richard Y. Lam, Stephen B. Strum, Dean J. LaBarba, Lauren K. Becker, Patricia Chang, Nojan Farhoumand, and Robert I. Jennrich. “Primary intermittent androgen deprivation as initial therapy for men with newly diagnosed prostate cancer.” Clinical Genitourinary Cancer 9, no. 2 (2011): 89-94.

De Bono, Johann S., Christopher J. Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N. Chi et al. “Abiraterone and increased survival in metastatic prostate cancer.” New England Journal of Medicine 364, no. 21 (2011): 1995-2005.

Scholz, Mark, Richard Lam, Stephen Strum, Robert Jennrich, Henry Johnson, and Tom Trilling. “Prostate cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone inactivating pharmaceuticals.” Urology 70, no. 3 (2007): 506-510.

Porter, Michael P. “Outcomes of treatment vs observation of localized prostate cancer in elderly men.” Letter to Editor. Jama 297, no. 15 (2007): 1651-1653.

Shaw, G., J. Cuzick, L.Goldenberg, N. Spry, D. Prapotnich, S. Malone, J. Foran, M. Scholz, W. Albrecht, and T. Oliver. “Pragmatic Recommendation and Directions for Future Work Base on a Meta-Analysis of 1653 Patients treated with Intermittent Hormone Therapy (IHT) for Adenocarcinoma of the Prostate.” Journal of Urology 68 Supplement 3 (2006): 5A.

Scholz, Mark C., Robert I. Jennrich, Stephen B. Strum, Henry J. Johnson, Brad W. Guess, and Richard Y. Lam. “Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period.” The Journal of Urology 175, no. 5 (2006): 1673-1678.

Guess, B., M. Scholz, and R. Lam. “Preventing and Treating the Side Effects of Testosterone Inactivating Pharmaceuticals in Men with Prostate Cancer.” Seminars in Preventative and Alternative Medicine (2006).

Scholz, Mark, Robert Jennrich, Stephen Strum, Stanley Brosman, Henry Johnson, and Richard Lam. “Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.” The Journal of Urology 173, no. 6 (2005): 1947-1952.

Guess, B. W., M. C. Scholz, S. B. Strum, R. Y. Lam, H. J. Johnson, and R. I. Jennrich. “Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study.” Prostate cancer and prostatic diseases 6, no. 4 (2003): 301-304.

Scholz, M., S. Strum, F. Berrios, B. Leibowitz, and B. Guess. “Low-Dose Single-Agent Weekly Docetaxel (Taxotere) is Effective and Well Tolerated in Elderly Men with Prostate Cancer.” Advances in Prostate Cancer 5, no. 3 (2001).

Guess, B., and M. Scholz. “RE: Failure to Achieve Castrate Levels of Testosterone During Luteinizing Hormone Releasing Hormone Agonist Therapy: The Case for Monitoring Serum Testosterone and a Treatment Decision Algorithm.” Letter to the Editor, Journal of Urology 165 (2001): 1644-1645.

Scholz, M., and S. Strum. “RE: Prostate Specific Antigen: A Decade of Discovery—What We Have Learned and Where we are Going.” Letter to the Editor, Journal of Urology 163 (2000): 1259-1260.

Strum, Stephen B., Mark C. Scholz, and Jonathan E. McDermed. “Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy.” The Oncologist 5, no. 1 (2000): 45-52.

Guess, Brad, Robert Jennrich, Henry Johnson, Ray Redheffer, and Mark Scholz. “Using splines to detect changes in PSA doubling times.” The Prostate 54, no. 2 (2003): 88-94.

Scholz, M., and S. Strum. “RE: Recovery of Spontaneous Erectile Function After Nerve-Sparing Radical Retropubic Prostatectomy With and Without Early Intracavernous Injections of Alprostadil.” Letter to the Editor, Journal of Urology 161 (1999): 1914-1915.

Strum, S. B., J. E. McDermed, M. C. Scholz, H. Johnson, and G. Tisman. “Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade.” British Journal of Urology 79, no. 6 (1997): 933-941.

Gill, I., P. Guaglianone, S. M. Grunberg, M. Scholz, and F. M. Muggia. “High dose intensity of cisplatin and etoposide in adenocarcinoma of unknown primary.” Anticancer Research 11, no. 3 (1990): 1231-1235.

Abstracts and Posters

Scholz, M., Chi, Kim., Fleming, M., Sunderland, K., Albany C., Gingerich, J., Saad, F., North, S., Starodub, A., Lauer, R., Ruether, J., Sgroi, M., Sweeney, C. “PACIFIC Trial: A Randomized Phase II Study of Apatorsen and Abiraterone (ABI) in Patients (Pts) with Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Who Have Had PSA Progression While Receiving Abiraterone (ABI).” Abstract. Genitourinary Cancers Symposium. (2017).

Scholz, M., Chancey, M., Yep, S., De Guzman, K., Kelly, C. “Phase I sipuleucel-T combined with escalating does of ipilimumab (SIPIPI) in progressive M-CRPC.” Abstract. ASCO 2017 Cancer Survivorship Symposium. (2017).

Scholz, M., Yep, S., Kelly, C., Chau, KN., Turner, J., Lam, R. “Phase I trial of sipuleucel-T combined with ipilimumab (SIPIPI) in progressive M-CRPC.” Abstract. ASCO Gastrointestinal Cancers Symposium. (2016).

Scholz, M., Lam, R., Turner, J., Felarca, CU. “Y-90 resin in castrate-resistant prostate cancer with liver metastasis.” Abstract. ASCO Gastrointestinal Cancers Symposium. (2016).

Scholz, M., Yep, S., Kelly, C., Chau, KN., Turner, J., Lam, R. “Phase I trial of sipuleucel-T combined with ipilimumab (SIPIPI) in progressive M-CRPC.” Abstract. ASCO – Genitourinary Symposium (February 2016).

Scholz, M., Lam, R., Turner, J. “Sir-Spheres (SS) for prostate cancer (PC) metastatic to liver.” Abstract. Genitoury Cancers Symposium (2016).

Almeida, F.D., Finkelstein S.E., Bans, L.L., Lipson, R., Scholz, M.C., Lam, R.Y., Turner, J.T. “Performance Characteristics and Influence of PSA Value/Kinetics on Carbon-11 Acetate PET/CT Imaging in Biochemical Relapse of Prostate Cancer.” International Prostate Cancer Update (IPCU) (2016).

Sartor, A.O., Cooperberg, M.R., Armstrong, A.J., Vogelzang, N.J., Vacirca, J.L., Scholz, M., Dakhil, S.R., Nordquist, L.T., Heath, E.I., Chang, N.N., Susan LIII, J., Higano, C.S. “Real-world experience of therapeutic sequencing and time to first anticancer intervention (ACI) following sipuleuce-T (sip-T): initial data form the PROCEED registry.” Abstract. ASCO-GU (2016)

Scholz, M., Joshua A., Shore, N., Saad, F., Chi, K., Olsson, C., Emmeenegger, U., Berry, W., Mukherjee, S., Winquist, E., Haas, N., Foley, M., Dmuchowski, C., Perabo, F., Hirmand, M., Hasabou, N., Rathkopt, D., “Safety of Enzalutamide in Patients with Castrate-Resistant Prostate Cancer Previously Treated with Docetaxel: Expanded Access in North America.” Abstract. Wiley Periodicals, Inc. (2015).

Crawford, E.D., Scholz, M., Kar, A., Fegan, J., Haregewoin, A., Kaldate, R., and M. Brawer. “Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry.” Abstract. Current Medical Research & Opinion (CMRO) (2014).

Scholz, M., “Safety results of the enzalutamide expanded access program in the U.S. and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.” Abstract. ASCO-GU (2014)

Scholz, M., “Cell cycle progression (CCp) score significantly modifies treatment decisions in prostate cancer: Results of an ongoing registry trial.” Abstract. ASCO-GU (2014)

Scholz, M., “Real-world experience with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received prior docetaxel (D): Data from PROCEED.” Abstract. ASCO-GU (2013).

Scholz, M., “Experience with sipuleucel-t (Sip-T) in a community oncology clinic: Initial 50 patients (pts).” Abstract. ASCO-GU (2012).

Scholz, M., “Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy.” Results from the Prostate Cancer Results Study Group.” Abstract. BJU International (2012): Vol. 109.

Scholz, M., “Abiraterone and Increased Survival in Metastatic Prostate Cancer.” Abstract. New England Journal of Medicine (2011).

Scholz, M., Lam, R., Strum, S., and H. Johnson. “Active Surveillance after Induction with Testosterone Inactivating Pharmaceuticals (TIP): Ten Year Outcome.” Abstract. Active Surveillance Symposium 10 (2007).

Scholz, M., Lam, R., Jennrich, R., Strum, S., Guess, B., and H. Johnson. “Ultra-sensitive PSA Nadir on Testosterone-Inactivating-Pharmaceuticals Accurately Predicts Early Prostate Cancer Progression.” Abstract. Prostate Cancer Symposium (2006):40.

Lam, R., Scholz, M., Guess, B., Trilling, T., and H. Goodman. “Oral Bisphosphonates Fail to Prevent Bone Loss form Androgen Deprivation Therapy in Men with Prostate Cancer.” Abstract. Prostate Cancer Symposium (2006):122.

Strum, S., and M. Scholz. “Optimized Imaging in Prostate Cancer is Absent 95% of the Time at Diagnosis or PSA Recurrence.” Abstract. Prostate Cancer Symposium (2006): 68.

Scholz, M.C., Jennrich, R.I., Strum, S.B., Johnson, H., Guess, B.G., and R.Y. Lam. “Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time-Off Period.” Journal of Urology (2006): 175.

Scholz, M., Lam, R., Strum, S., Johnson, H., Trilling T., and R. Jennrich. “Intermittent Use of Testosterone-Inactivating-Pharmaceuticals using Finasteride during Testosterone-Recovery Prolongs the Time-Off-Period.” Abstract. Multidisciplinary Prostate Cancer Symposium (2005): 153.

Lam, R., Scholz, M., Guess, B., Mahoney, J., Johnson, H., Trilling, T., and H. Goodman “Oral Bisphosphonates for the Prevention of Androgen Deprivation Therapy Associated Bone Loss.” Abstract. ASCO (2004): 4749.

Scholz, M., Johnson, J., Guess, B., and R. Lam. “Extent of Disease on Bone Scan, Baseline Alkaline Phosphatase, and 80% Decline in PSA are the Best Indicators Predicting Long Term Survival in Men with Androgen Independent Prostate Cancer Treated with Ketoconazole and Hydrocortisone.” Abstract. Western AUA (2003).

Scholz, M., Guess, B., and R. Lam. “Calcitriol Restores Docetaxol Anticancer Activity in Men with Androgen Independent Prostate Cancer Who Previously Progressed on Docetaxol.” Abstract. Western AUA (2003).

Scholz, M., Guess, B., Barrios, F., Strum, S., and B. Leibowitz. “Low-dose Single-Agent Weekly Taxotere is Effective and Well Tolerated in Elderly Men with Prostate Cancer.” Abstract. ASCO (2001).

Seltzer, M., Strum, S., Scholz, M., Belldegrun, A., and N. Satyamruthy. “Comparison of Whole Body C-11 Acetate and FDG PET in Patients with Prostate Cancer.” Abstract. Nuclear Medicine (1999).

Scholz, M., Strum, S., and P. Mittelman. “High-Dose Ketoconozole and Hydrocortisone for Hormone Refractory Prostate Cancer.” Abstract. ASCO (1999).

Scholz, M., Strum, S., and J. McDermed. “Intermittent Androgen Deprivation (IAD) with Finasteride (F) During Induction and Maintenance Permits Prolonged Time off IAD in Localized Prostate Cancer (LPC).” Presented by Dr. Scholz. The Journal of Urology (April 1999).

Scholz, M., and S. Strum. “Phase II Trial of Weekly Low-Dose Taxotere in the Treatment of Patients with Hormone Refractory Prostate Cancer.” Abstract. ASCO (1999).

Strum, S., and M. Scholz. “A Phase II Trial of Taxotere and Emcyt for Metastatic Prostate Cancer.” Abstract. ASCO (1999).

Scholz, M., Strum, S., Madsen, L., and J. McDermed. “Intermittent Androgen Deprivation (IAD) Therapy for Prostate Cancer: PSA Response on Cycle 1 Can Predict Response on Subsequent Cycles.” ASCO (1999).

Scholz, M., Strum, S., McDermed, J., and L. Madsen. “Intermittent Androgen Deprivation (IAD) with Finasteride Given During the Induction and Maintenance Periods Results in Prolonged Time off IAD in Patients with Localize Prostate Cancer.” ASCO (1999).

Scholz, M.C., Strum, S.B, and J.E. McDermed. “A Phase II Trial of Taxotere (t)/Estramustine (e) Combination in P(pts) with Prostate Cancer (pc). Accepted for publication at ASCO (1998).

Scholz, M.C., McDermed, J.E., and S.B. Strum. “Intermittent Hormone Blockade (IHB): Optimal Induction Duration and Predictive Factors for Prolonged time Off Hormone Blockade (HB).” Poster presented at the Xth International Congress on Hormonal Steroids (1998).

Scholz, M.C., McDermed, J.E., and S.B. Strum. “Combined Hormone Blockade (CHB) Induction and Finasteride Maintenance (FM) Permits Discontinuation of CHB for Prolonged Periods in Patients with Low-Volume (LV) Prostate Cancer (PC).” Abstract. Xth International Congress on Hormonal Steroids (1998).

Tisman, G., Strum, S.B., Scholz, M.C., et al. “Computer Assisted, Tumor Volume-Based Decision Making in Expectant Management of Early Stage Prostate Cancer. Abstract. AUA (1997): 1480.

Scholz, M.C., Strum, S.B., McDermed, J.E., Tisman, G., and H. Johnson. “Prolonged Non-Detectable PSA (NDPSA) in Patients (PTS) Receiving Combination Hormone Blockade (CHB) Allows for Discontinuation of Androgen Blockade.” Abstract. AUA (1997): 1478.

Strum, S.B., Scholz, M.C. and J.E. McDermed. “The Androgen Deprivation Syndrome: the Incidence and Severity in Prostate Cancer Patients Receiving Hormone Blockade.” Abstract. ASCO (1998).

Strum, S.B. and M.C. Scholz. “Intermittent Hormone Blockade (IHB) in Prostate Cancer (PC) Patients: Duration of Non-Detectable PSA (NDPSA) on Androgen Blockade Relates to Time Off Treatment.” Abstract. 7th International Congress on Anti-Cancer Treatment. (1997).

Tisman, G., Strum S.B., Scholz, M.C., et al. “Pre-therapy Prediction of the Duration of Post-Therapy Non Detectable PSA for Prostate Cancer Patients Considering Intermittent Combine Hormonal Blockade.” Abstract. ASCO. (1997).

Strum, S.B., McDermed, J.E., Scholz, M.C., Tisman, G., and H. Johnson. “Anemia Associated with Androgen Deprivation (AAAD) Due to Combination Hormone Blockade (CHB) Responds to Recombinant Human Erythropoietin (r hu-EPO).” Abstact. AUA (1997): 1483.

Strum, S.B., McDermed, J.E., Scholz, M.C. et al. “Anemia Associated with Androgen Deprivation (AAAD) in Prostate Cancer (PC) Patients (PTS) Receiving Combination Hormone Blockade (CHB).” ASCO (1997): 16, 345a.

Strum, S.B., McDermed, J., Scholz, M.C., et al. “Time to Non-Detectable (TTND) PSA in Prostate Cancer (PC) Patients on Combination Hormone Blockade (CHB) Predicts Favorable Outcomes.” ASCO (1997): 16, 345a.

Strum, S.B., McDermed, J.E., Scholz, M.C., Tisman, G., and H. Johnson. “Anemia Associated with Androgen Deprivation (AAAD) Due to Combination Hormone Blockade (CHB) Responds to Recombinant Human Erythropoietin (r hu-EPO).” Abstract. Journal of Urology (1997): 157, 232.

Tisman, G., Strum, S.B., Scholz, M.C., and J. McDermed. “Pre-Therapy Prediction of the Duration of Post-Therapy Non-Detectable PSA for Prostate Cancer Patients Considering Intermittent Combined Hormone Blockade by Use of Computerized Neural Net Modeling. Abstract. ASCO (1997).

Strum, S.B., McDermed, J.E., Scholz, M.C., Tisman, G., and H. Johnson. “Intermittent Hormone Blockade (IHB) in Prostate Cancer (PC) Patients (PTS): Duration of Non-Detectable PSA (NDPSA) on Androgen Blockade Relates to Time off Treatment. Abstract. 7th International Chemotherapy Congress (1997).

Strum, S.B., McDermed, J.E., Scholz, M.C., Johnson, H.J., and G. Tisman. “Anemia Associated with Androgen Deprivation (AAAD) in Prostate Cancer (PC) Patients (PTS) Receiving Combination Hormone Blockade (CHB).” Abstract. ASCO (1997).

Strum, S., McDermed, J., Scholz, M.C., and G. Tisman. “Time to Non-detectable (TTND) PSA in Prostate Cancer (PC) Patients on Combination Hormone Blockade (CHB) Predicts Favorable Outcomes.” Abstract. ASCO (1997).

Strum, S.B., McDermed, J.E., Scholz, M.C., Tisman, G., and H. Johnson. Anemia Associated with Androgen Deprivation in Prostate Cancer (PC) Patients on Combination Hormone Blockade (CHB). Abstract. AUA (1997): 1481.

Tisman, G., Strum, S.B., Scholz, M.C., McDermed, J.E., and H. Johnson. “Computer-Assisted, Tumor Volume-Based Decision Making in Expectant Management of Early Stage Prostate Cancer.” Abstact. AUA (1997): 1480.

Scholz, M.C., Grunberg, S., Muggia, F.M., Rosen, P., and L. Leishman. “Phase I Study of TMCA.” Abstact. AACR.

Scholz, M.C., Strum, S.B., McDermed, J.E., Tisman, G., and H. Johnson. “Prolonged Non-Detectable PSA (NDPSA) in Patients (PTS) Receiving Combination Hormone Blockade (CHB) Allows for Discontinuation of Androgen Blockade. Abstract. AUA. (1997): 1478.

Strum, S.B., Scholz, M.C., and M. Strum. “Prolonged Non-Detectable PSA (NDPSA) in PC Patients Treated with Androgen Deprivation may allow for Discontinuation of Hormone Blockade.” Poster presented at the International Symposium on Recent Advances in Diagnosis & Treatment of Prostate Cancer, Abstract (1995).

CLINICAL TRIALS

Principal Investigator

10TASQ10: A Phase III Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men Metastatic Castrate Resistant Prostate Cancer.

212082PCR3001: An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed after Taxane-based Chemotherapy.

9785-CL-0401: A Multicenter, Single-arm, Open Label Treatment Protocol to Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy.

ABT627: A Phase II/III Extension study to Evaluate the Safety and Tolerability of Atrasentan.

BMS184-043: A Randomized, Double-blind, Phase III Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer that Have Received Prior Treatment with Docetaxel.

CA184-095: A Randomized, Double-blind, Phase III Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer.

CC-5013-PC-002: A Phase III Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone with or without Lenolidomide in Subjects with Castrate-Resistant Prostate Cancer.

COU-AA-301: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy.

COU-AA-302: A Phase III, Randomized, Double-blind, Placebo-controlled study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer.

CRPC2: A Multinational Phase III, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy.

EN99-01: A Phase II Study to Determine the Effectiveness of Pecta-Sol in Prostate Cancer.

GU 115/I6A-MC-CBBD: A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer.
GU12-159: A Randomized Phase II Study Evaluating OGX-427 in Patients with Metastatic Castrate-Resistant Prostate Cancer Who Have PSA Progression While Receiving Abiraterone.

MDV3100-09: A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy.

OGX-011-11: A Randomized Phase III Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custirsen (OGX-011) in Men with Metastatic Castrate-Resistant Prostate Cancer.

OGX-011-12: A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY).

ONC-MA-1004: A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States.

P10-3 PROCEED: A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer.

P11-3: A Randomized, Open-label, Phase 2 Trial of Sipuleucel-T With Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC).

P11-4: Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T.

P12-1: A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer.

PROCEDE-1000: An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients.

SIPIPI 2013: Phase 1 Study of Sipuleucel-T and Ipilimumab in Combination for Advanced Prostate Cancer.

SP005: A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy.

TAX-327: A Multicenter Phase III Randomized Trial Comparing Docetaxel Administrated Either Weekly or Every Three Weeks in Combination with Prednisone Versus Mitoxantrone in Combination with Prednisone for Metastatic Hormone Refractory Prostate Cancer.

TOK-200-15: A Phase 3, Randomized, Open Label, Multicenter, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC).

XL184-306: A Phase III, Randomized, Double-blind, Controlled Trial of Cabzantinib (XL184) vs. Mitoxantrone Plus Prednisone in Men with Previously Treated Symptomatic Castration-resistant Prostate Cancer.

Sub-Investigator

CRITICAL-001: A Phase I/IIa Trial of Combined Cryotherapy and Intra-turmoral Immunotherapy with Autologous Immature Denritic Cells (VCD2008) in Chemo-naïve Men with Prostatic Adenocarcinoma and Limited Metastases to Lymph Nodes and/or Bone.